Compare CAR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAR | LQDA |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.8B |
| IPO Year | 1998 | 2020 |
| Metric | CAR | LQDA |
|---|---|---|
| Price | $112.09 | $41.96 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $116.43 | $54.38 |
| AVG Volume (30 Days) | 342.7K | ★ 4.7M |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.71 | ★ 51.81 |
| EPS | N/A | ★ 1.26 |
| Revenue | ★ $11,652,000,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $357.27 |
| Revenue Next Year | $1.53 | $1.34 |
| P/E Ratio | ★ N/A | $35.87 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $85.96 | $22.31 |
| 52 Week High | $847.70 | $93.61 |
| Indicator | CAR | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 46.89 |
| Support Level | $95.15 | $35.00 |
| Resistance Level | $113.37 | $46.67 |
| Average True Range (ATR) | 4.99 | 3.03 |
| MACD | 1.72 | 2.27 |
| Stochastic Oscillator | 83.82 | 68.63 |
Avis Budget Group Inc is a provider of mobility solutions through its three brands Avis, Budget and Zipcar, as well as several other brands, well recognized in their respective markets. Its brands offer a range of options, from car and truck rental to car sharing. The company operates in two reportable business segments: Americas - (i) vehicle rental operations in North America, South America, Central America and the Caribbean, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly. International - consisting of (i) vehicle rental operations in Europe, the Middle East, Africa, Asia and Australasia, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.